Cancer Biol Ther December 2023 PMID 37272701

Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments.

Lanshu Xiao, Yi Liu, Hui Chen, Lisong Shen

Download social card

Mentions

Peak: 7 in Jun 2023

across 2 sources since Jun 2023

Extended reach

12,633

potential audience

Total likes

Video views

239

Mentions per month

Jun 2023 – Dec 2025

Where it's discussed

X / Twitter7 posts
YouTube2 videos

AI synopsis

What people are saying

The discussions emphasize the promising potential of drugs like VIP152 in clinical trials and highlight the need for further research, with tone conveying both optimism and curiosity. Phrases such as 'recent developments' and mentions of specific inhibitors reflect a positive view and interest in emerging therapies, indicating collective engagement and acknowledgment of the publication’s potential impact.

AgreementModerate agreement

Most discussions recognize the significance of recent advancements in targeting CDK9 for tumor therapy, showing general agreement with the research's importance.

InterestHigh interest

The high interest score reflects enthusiasm and curiosity expressed about the potential of CDK9 inhibitors and degraders in cancer treatment.

EngagementModerate engagement

Posts demonstrate a moderate level of engagement by referencing specific drug names and implying interest in clinical implications.

ImpactModerate impact

The recognition of the research’s potential to influence cancer therapy approaches explains the moderate impact score.

Abstract in brief

This review discusses recent advancements in developing selective CDK9 inhibitors and PROTAC degraders as potential cancer therapies, highlighting their structures, effectiveness, and mechanisms of action.
Most of these inhibitors, such as NVP2 and MC180295, are designed primarily for solid tumors and tend to work only on specific tumor genotypes, with VIP152 showing promise in clinical trials for high-grade lymphoma and solid tumors.
Further research is needed to better understand how these drugs work at the molecular level, identify the best patient populations for treatment, and develop effective combination therapies to improve their success in cancer treatment.]

Read the full abstract

All mentions

Molecular Dynamics Simulation of Zotatifin–eIF4A–RNA Complex

Brief molecular dynamic simulation of a hypothesized Zotatifin-eIF4A-Polypurine RNA complex. Zotatifin, an eIF4A helicase inhibitor in clinical trials, was modeled with initial conditions including Roca binding and…

LabPsycho · Nov 12, 2023 174 views

Molecular Dynamics Simulation of Telomerase-Related DNA Complexes

This brief molecular dynamics simulation investigates 2Deoxy6Thioguanosine Phosphate's interaction with telomerase and telomeric DNA, using software like VMD, NAMD, and OpenMM to model and analyze the complex's…

LabPsycho · Dec 28, 2025 65 views

Sehbanul Islam

@sehbanamu · X

RT @Glaconde34: Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments https://t.co/VPO…

Jun 9, 2023 · 1 share · 640 followers View post →

Guillaume Laconde

@Glaconde34 · X

Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments https://t.co/VPOoXxiNTq

Jun 9, 2023 · 8 likes · 1 share · 4,921 followers View post →

Protein-Degraders

@ProtDegraders · X

RT @Glaconde34: Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments https://t.co/VPO…

Jun 6, 2023 · 4 shares · 493 followers View post →

Dieter

@Wuhle · X

RT @Glaconde34: Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments https://t.co/VPO…

Jun 6, 2023 · 4 shares · 508 followers View post →

Ivan Alfaro

@alfobioq · X

RT @Glaconde34: Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments https://t.co/VPO…

Jun 5, 2023 · 4 shares · 819 followers View post →

Jong Yeon Hwang

@jy_hwang · X

RT @Glaconde34: Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments https://t.co/VPO…

Jun 5, 2023 · 4 shares · 49 followers View post →

Guillaume Laconde

@Glaconde34 · X

Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments https://t.co/VPOoXxiNTq

Jun 5, 2023 · 7 likes · 4 shares · 4,921 followers View post →

Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments.

Mentions per month

Where it's discussed

What people are saying

Abstract in brief

Top posts

All mentions

Molecular Dynamics Simulation of Zotatifin–eIF4A–RNA Complex

Molecular Dynamics Simulation of Telomerase-Related DNA Complexes